Cargando…
Letter regarding the article, “A randomized, double- blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients”
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345323/ https://www.ncbi.nlm.nih.gov/pubmed/30718943 http://dx.doi.org/10.2147/DDDT.S185297 |
_version_ | 1783389552190160896 |
---|---|
author | Zhao, Ling-Yue Luo, Yi-Jun Zhu, Jing |
author_facet | Zhao, Ling-Yue Luo, Yi-Jun Zhu, Jing |
author_sort | Zhao, Ling-Yue |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-6345323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63453232019-02-04 Letter regarding the article, “A randomized, double- blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients” Zhao, Ling-Yue Luo, Yi-Jun Zhu, Jing Drug Des Devel Ther Letter Dove Medical Press 2019-01-21 /pmc/articles/PMC6345323/ /pubmed/30718943 http://dx.doi.org/10.2147/DDDT.S185297 Text en © 2019 Zhao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Letter Zhao, Ling-Yue Luo, Yi-Jun Zhu, Jing Letter regarding the article, “A randomized, double- blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients” |
title | Letter regarding the article, “A randomized, double- blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients” |
title_full | Letter regarding the article, “A randomized, double- blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients” |
title_fullStr | Letter regarding the article, “A randomized, double- blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients” |
title_full_unstemmed | Letter regarding the article, “A randomized, double- blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients” |
title_short | Letter regarding the article, “A randomized, double- blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients” |
title_sort | letter regarding the article, “a randomized, double- blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin ii receptor blockers in hypertensive type 2 diabetic patients” |
topic | Letter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345323/ https://www.ncbi.nlm.nih.gov/pubmed/30718943 http://dx.doi.org/10.2147/DDDT.S185297 |
work_keys_str_mv | AT zhaolingyue letterregardingthearticlearandomizeddoubleblindclinicaltrialofcanrenonevshydrochlorothiazideinadditiontoangiotensiniireceptorblockersinhypertensivetype2diabeticpatients AT luoyijun letterregardingthearticlearandomizeddoubleblindclinicaltrialofcanrenonevshydrochlorothiazideinadditiontoangiotensiniireceptorblockersinhypertensivetype2diabeticpatients AT zhujing letterregardingthearticlearandomizeddoubleblindclinicaltrialofcanrenonevshydrochlorothiazideinadditiontoangiotensiniireceptorblockersinhypertensivetype2diabeticpatients |